Intrexon Appoints Dr. Mark Carnegie-Brown As CEO Of Oxitec

GERMANTOWN, Md., May 18, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the appointment of Mark Carnegie-Brown, Ph.D. as Chief Executive Officer of its wholly owned subsidiary Oxitec Ltd.  Dr. Carnegie-Brown succeeds Hadyn Parry, who has been appointed Vice President, Corporate Development Europe, the Middle East, and Africa (EMEA) for Intrexon to strengthen its management ranks abroad as it continues to expand its global presence.

Intrexon Corporation logo. (PRNewsFoto/Intrexon Corporation)

"I am delighted to be joining Oxitec and look forward to advancing its pioneering solutions including Friendly Aedes," Dr. Carnegie-Brown stated.  "I believe the Company's technology represents a paradigm shift in controlling both disease-carrying insects, including dangerous Aedes aegypti mosquitoes, and damaging agricultural pests that are increasingly resistant to chemical insecticides."

Dr. Carnegie-Brown joins Oxitec with over 25 years leadership in the life science and health science industries. This includes strategic and operational experience in agrochemicals, drug development, contract manufacturing and drug delivery businesses.  Prior to joining Oxitec, he was Chief Executive Officer of Glide Technologies and led the business to develop a proven therapeutic delivery platform, generate positive clinical results, and build a scalable manufacturing line.  Before joining Glide Dr. Carnegie-Brown was General Manager of Zeneca's Agrochemical business in the United Kingdom and Ireland where he developed and implemented a cutting edge value chain strategy and drove transformation toward an organization attuned to consumers.  He also previously served as Chief Executive Officer of Evolutec plc, a biological drug development business.  Dr. Carnegie-Brown received a Ph.D. in Applied Biology with a specialty in pesticide resistance from Manchester University.

Concurrent with Dr. Carnegie-Brown's appointment, Mr. Parry will move to a broader corporate role to support numerous functions abroad with specific responsibility for developing and expanding Intrexon's interests and business opportunities in EMEA.  His business acumen, strong communication skills, and ability to engage at all levels of business from government to corporations to consumers will be a key asset to Intrexon.

"It has been a real privilege to lead Oxitec over the last few years and to help develop such a promising technology into a truly operational solution that is much needed around the world. I now look forward to supporting the growth of Intrexon's broader business," said Mr. Parry.

Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, commented, "We welcome Mark at the helm of Oxitec, the leading engineered insect capability in the world, and its exemplary team of scientists who are doing so much to address some of the most pressing needs in human disease vector control and crop protection against insect pests.  And we welcome Hadyn, who so capably led Oxitec to its world leading position, to a role of even greater responsibility as he helps us to expand Intrexon's reach and penetration across multiple opportunities offering similar impact."

About Oxitec 
Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK).  Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world's biggest problems.  Follow us on Twitter at @Oxitec.

About Intrexon Corporation:  
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet.  Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.

Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement 
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information regarding Intrexon Corporation, contact:

Investor Contact:

Christopher Basta

Vice President, Investor Relations

Tel: +1 (561) 410-7052

Corporate Contact:

Marie Rossi, Ph.D.

Director, Technical Communications

Tel: +1 (301) 556-9850



To view the original version on PR Newswire, visit:

SOURCE Intrexon Corporation

Back to news